Home | Drugs | Adverse Events | Conditions | Indications | Subscribe
Drug Report: VANCOCIN (VANCOMYCIN)
Primary Suspect Reports: 3,968 Total Reports: 17,735 FDA AERS Reports from 11/01/1997 to 08/27/2012
Drug Description :

Vancocin (vancomycin) is an antibiotic used in the prevention and treatment of certain bacterial infections. It is indicated for the treatment of C. difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains). Vancocin was FDA approved on April 15, 1986 and is manufactured by ViroPharma, Inc.

From 11/01/1997 to 08/27/2012, there have been 3,968 reports of a serious adverse event where VANCOCIN was identified as the primary suspect drug causing that event. During that time period, the top three adverse events reported in cases where VANCOCIN was identified as the primary suspect drug were: Pruritus, Pyrexia and Renal Failure Acute.

Drug Safety Monitor News :

08/20/2012 - Study Finds Cefazolin More Effective Than Vancomycin for Treatment of Bloodstream Infections
Other Names : Generic Name : Report Info:

Oral Vancomycin

VANCOMYCIN

Average Age: 55 Years
Gender: 55% M, 45% F
Average Duration of Treatment: 32 Days
FDA Listed Names (422) : How to read this section Manufacturer: Common Conditions:

(vancomycin)
Antifungal Vancomycin
Blinded *vancomycin
Show All

Eli Lilly & Company (839)
Hospira, Inc. (274)
Baxter Healthcare Corporation (130)
STAPHYLOCOCCAL INFECTION
INFECTION
SEPSIS

  Important Disclosures*
VANCOCIN Adverse Event Timeline
Top VANCOCIN Adverse Events/Side Effects How to read this section
How to read this section
Side Effects
MedDRA Preferred Terms		 VANCOCIN Primary Suspect Reports VANCOCIN Total Reports ROR Score
How to read this section 		PRR Score
How to read this section 		Compare Top Drugs
Pruritus 385 (10%) 660 (4%) Premium Feature Premium Feature
Pyrexia 361 (9%) 1,978 (11%) Premium Feature Premium Feature
Renal Failure Acute 338 (9%) 1,324 (7%) Premium Feature Premium Feature
Rash 282 (7%) 711 (4%) Premium Feature Premium Feature
Dermatitis 235 (6%) 477 (3%) Premium Feature Premium Feature
Hypotension 184 (5%) 1,053 (6%) Premium Feature Premium Feature
Rash Erythematous 171 (4%) 388 (2%) Premium Feature Premium Feature
Erythema 169 (4%) 399 (2%) Premium Feature Premium Feature
Blood Creatinine Increased 162 (4%) 722 (4%) Premium Feature Premium Feature
Urticaria 159 (4%) 267 (2%) Premium Feature Premium Feature
Data downloads, Grouping Adverse Events by different MedDRA levels and PRR/ROR calculations are reserved for our Premium Subscribers.
Click here to learn more about subscription levels and pricing.
Click here to view a sample report that includes the premium sections.
Reported Report Outcomes for VANCOCIN Adverse Events
Report Outcomes VANCOCIN Primary Suspect
(# of Reports)
(11/01/1997 to 08/27/2012) 		VANCOCIN Total
(# of Reports)
(11/01/1997 to 08/27/2012)
Hospitalization - Initial or Prolonged 1,538 (39%) 8,471 (48%)
Other 1,453 (37%) 6,507 (37%)
Required Intervention to Prevent Permanent Impairment/Damage 584 (15%) 1,501 (8%)
Life-Threatening 397 (10%) 2,599 (15%)
Death 373 (9%) 4,477 (25%)
Disability 149 (4%) 693 (4%)
Most Recent VANCOCIN Report Reviews/FDA Reports (Primary Suspect)
Report Date Age Gender Conditions Adverse Events Outcome
08/24/2012 Not Stated F Clostridial Infection
 Drug Ineffective
 Other
08/24/2012 60 YR F Anxiety
Breast Cancer Metastatic
Nephrolithiasis

Show All 		Renal Failure Acute
Hypoxia
Multi-organ Failure

Show All 		Death
Hospitalization - Initial or Prolonged
08/23/2012 57 YR F Infection
 Shock
Rash Pruritic
Hypokalaemia

Show All 		Hospitalization - Initial or Prolonged
08/21/2012 74 YR M Pneumonia
 Renal Failure
Respiratory Disorder
Pneumonia
 Death
Hospitalization - Initial or Prolonged
08/21/2012 18 YR M Osteomyelitis Chronic
Staphylococcal Osteomyelitis
 Blood Creatine Phosphokinase Increased
Decreased Appetite
Bone Marrow Failure

Show All 		Other
08/21/2012 59 YR M Hypertension
Infection Prophylaxis
Surgery
 Osteomyelitis
Diabetic Neuropathic Ulcer
Toe Amputation

Show All 		Life-Threatening
Required Intervention to Prevent Permanent Impairment/Damage
08/20/2012 65 YR M Evidence Based Treatment
 Drug Rash With Eosinophilia And Systemic Symptoms
Oedema Mucosal
Metabolic Acidosis

Show All 		Hospitalization - Initial or Prolonged
08/17/2012 70 YR M Candidiasis
Septic Shock
 Confusional State
Aggression
Disorientation
 Hospitalization - Initial or Prolonged
08/17/2012 91 YR F Bacteraemia
 International Normalised Ratio Increased
Drug Interaction
Overdose
 Other
08/17/2012 20 YR M Colitis Ulcerative
 Pruritus
 Not Stated

Downloading table data into CSV files is for Professional and Enterprise subscribers only.

Proceed to the signup page to view subscription benefits.

Copyright © 2013 Adverse Events, Inc. All rights reserved.
About Us | Contact | Privacy Policy | Terms of Use